posted on 2014-03-19, 03:02authored byXiaopeng Dong, Yingtao Hao, Yucheng Wei, Qiuwei Yin, Jiajun Du, Xiaogang Zhao
(A) PFS for all patients with negative or positive RRM1 expression. (B) PFS for patients receiving gemcitabine-based therapy. (C) PFS for patients receiving docetaxel-based therapy. (D) PFS for patients receiving vinorelbine-based therapy.